Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING - Significant expense categories (Details)

v3.26.3
SEGMENT REPORTING - Significant expense categories (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating Expenses:        
Loss from operations $ (8,615,424) $ (11,750,432) $ (29,526,720) $ (29,395,189)
Other income 453,556 170,306 1,390,823 350,130
Consolidated Net Loss 8,161,868 11,580,126 28,135,897 29,045,059
Life science | Operating segment        
Operating Expenses:        
PMN310 development program costs 5,171,867 8,761,024 19,221,406 21,537,975
Other non-employee research and development costs 487,854 214,128 991,139 712,712
Employee costs 2,009,568 1,520,463 6,040,046 4,016,788
Other general and administrative costs 946,135 1,254,817 3,274,129 3,127,714
Loss from operations 8,615,424 11,750,432 29,526,720 29,395,189
Other income (453,556) (170,306) (1,390,823) (350,130)
Consolidated Net Loss $ 8,161,868 $ 11,580,126 $ 28,135,897 $ 29,045,059